03/28/2023 | Press release | Distributed by Public on 03/28/2023 00:38
0148/00042005/en |
Other Inside Information (Substantial Other Inside Information (Substantial Information/ Major Development) |
ASBISC ENTERPRISES PLC |
ASBISC - ASBISC ENTERPRISES LTD |
Investment in Theramir Ltd
|
Current report No 5/2023 Legal basis: Art. 17 ust.1 MAR - inside information
Message: The price for the purchased shares was EUR 800,000. The acquisition was financed from the own Company's funds.Theramir Ltd is a Cypriot biotech company, founded in 2016, that deals with developing stem cell and RNA-based technologies for the diagnosis and treatment of cancer disease. Theramir's proprietary cancer therapeutics utilize microRNAs (miRNAs), a novel class of small non-coding RNAs that can regulate many genes and pathways involved in cancer growth and metastasis. The investment in Theramir Ltd is a continuity of the ASBIS Group's strategy is to diversify its activities by investing in companies from the biomedical sector that are at an early stage of development and which operate in a very promising market. In previous years ASBIS invested in biotechnology, companies including EMBIO Diagnostics Ltd, RSL Revolutionary Labs Ltd. and Promed Bioscience Ltd. |
Regulated Filing Date: 28/03/2023 09:26 |